NEW
Font size
WorksheetsONCO-LYMPIC QUIZ
Total questions: 25
Worksheet time: 51mins
Lenvatinib is dosed based on based on actual body weight: what is the right initial dose for patients greater than or equal to 60 kg?
12 mg once daily
8 mg once daily
4 mg twice daily
4 mg three times daily
24 mg once daily
Lenvatinib mean dose intensity of REFLECT Study is:
7.0 mg (for 8mg/day dose)
12 mg (for 12mg/day dose)
8.5 mg (for 12mg/day dose)
9.5 mg (for 12mg/day dose)
6.5 mg (for 8mg/day dose)
In REFLECT study, estimate of time to progression for Sorafenib is:
8.9 month
9.8 month
3.7 month
5.4 month
4.3 month
In the REFLECT Trial, the primary endpoint of OS was first tested for non-inferiority then for the superiority. The result shows Lenvatinib has demonstrated non-inferiority versus sorafenib in OS in patients with unresectable HCC. This statement is:
True
False
In REFLECT Study, efficacy outcomes in patients with HBV from the Asia-Pacific region were consistent with
those observed in patients with HBV in the overall study population. It shows significant data, this statement is:
Correct
False
I have no idea
Maybe
REFLECT study by investigator assestment (mRECIST) shows patient who use Lenvatinib achieved ..................... as high as 24,1%, and Sorafenib only 9,2%.
Objective Response Rate
Overall Survival
Overall Response Rate
Ondemande Survival Rate
Omaigat lupa
Avoid the following practices when selling prescription drugs, except:
Always mention a package insert / product information approved by local authority
Create your own promotional materials or use materials you find in internet
Start a discussion about off-label use to encourage the health provider
Discuss off-label information, in response to an unsolicited questions to responding because you understand the protocols
Using the most updated international package insert to show unapproved indication
On what information should pharmaceutical sales representatives educate physicians?
Efficacy information contained within the PI
Safety information contained within the PI
Both answers correct
Both answers wrong
Which of the following best describes off-label information?
It covers a use or uses of a product that are not included on the drug’s approved label
The most updated published study in international journals contained unapproved indication by local authority
Incorrect dosage and misleading use by daily practice
All of the above
Mutation in Tumor Suppressor Genes cause loss of function effects meaning they lose the ability to prevent the development of cancer cells. In some cases it is not defective but other mechanisms interfere with its expression or function. This statement is:
True
False
The abbreviation BRCA stands for BReast CAncer susceptibility gene. These tumor suppressor genes are human genes responsible for keeping mutating breast cells in check. The statement is:
true
False
Pathogenesis of breast cancer involves which of the following?
Genetic abnormalities
Hormonal influencers
Angiogenesis
All of the above
Which of the following is NOT a tumor characteristic used in TNM breast cancer staging?
Tumor size
HER2/neu status
Nodal involvement
Metastatis
If breast cancer spreads to the liver, the cancer is considered:
Primary liver cancer
Breast cancer with liver metastatic
Liver cancer with breast metastatic
A recurrent cancer
Which of the following is NOT a common site of breast cancer metastasis?
Brain
Bone
Liver
Heart
Which of the following factors is both prognostic and predictive for breast cancer?
ER/PR status
Tumor size
Nyerah dok
Cancer that returns after a period of time when it could not be detected is referred to as:
Locally advanced
Recurrent
Metastatic
What is TNBC?
Breast cancer that does not overexpress HER2, estrogen receptors, or progesterone
receptors
Surgical procedure in which the breast is removed but the axillary lymph nodes
and muscle tissue are left in place
Hypothalamic hormone that regulates the production of HER-2
Breast cancer that overexpress HER-2 receptors
The most common lenvatinib treatment-related adverse events (TRAEs; any grade) in SELECT study:
Hypertension
Hypotension
Diarrhea
Weight loss
Hand and foot syndrome
Recommended Doses for Specific Populations in SELECT study for patient with severe hepatic impairment (Child-Pugh C) is:
20 mg once daily
14 mg once daily
8 mg once daily
4 mg once daily
4 mg twice daily
History of previous thyroid cancer treatment in inclusion criteria of SELECT study consist:
Sorafenib, sunitinib, pazopanib and other
Only sorafenib
Only sunitinib
Sorafenib and Pazopanib
On study 303 (SELECT study), patient characteristic that show prior using VEGF-targeted therapy, minimal 1, in Lenvatinib treatment arm are:
25%
75%
79%
21%
In SELECT Study, PFS by patient that have NO previous VEGF-targeted therapy before, shows: ..... months by using Lenvatinib vs 3,6 month by using Placebo.
18,7 month
15,1 month
12,7 month
17,2 month
In SELECT study, which age group shows more significant result in PFS subgrup analysis by using Lenvatinib?
Less than 65 years
More than 65 years
In SELECT Study, no significant difference was observed in the Overall Survival. Why?
83% of patients in placebo group entered optional open label with lenvatinib
This is a cross-over study
placebo arm is ITT population
All of the answers above correct
